The Tech Group, Pepex partner to develop Trio systems and sensor modules

Pepex Biomedical, Inc., a privately held company that has developed an all new proprietary sensor technology known as "CCM™", announced today it has reached an agreement with The Tech Group , a division of West Pharmaceuticals Services, Inc., to be the premier manufacturer of the Trio™ systems and sensor modules.  The seven year contract also includes development and engineering services from Insight Product Development, whom will take over primary responsibility of design development and assist with transitioning to full scale manufacturing on custom equipment built by the Mikron Automation.  Pepex will take delivery of its first production cell, a Mikron G05 V4 to be used as a pilot production unit in the next few weeks.

"This is more than just a milestone for us," according to Pepex CEO, Steve Collins. "After a long and comprehensive search it was ultimately the extraordinary effort by The Tech Group, Insight, and Mikron that proved to us that they are the kind of partners we want to be in business with.  The synergies between these three companies and history of working together are so exceptional that Pepex believes this is just the tip of the iceberg in what will be a long and rewarding relationship."

Source:

Pepex Biomedical, Inc.

Comments

  1. Curly Surmudgeon Curly Surmudgeon United States says:

    Pepex was taken over by venture capitalists who promptly discharged the team who brought this technology to fruition.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combination therapy shows promising results in treating stage 3 melanoma